Other research analysts have also recently issued reports about the stock. TheStreet raised shares of Eagle Pharmaceuticals from a c+ rating to a b- rating in a research note on Thursday, September 19th. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a hold rating to a strong sell rating in a research note on Thursday, October 17th. BidaskClub raised shares of Eagle Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada reissued a buy rating and issued a $66.00 price objective on shares of Eagle Pharmaceuticals in a research note on Sunday, August 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $59.00.
Shares of NASDAQ:EGRX opened at $62.34 on Friday. The company’s 50 day simple moving average is $58.31 and its 200 day simple moving average is $54.90. The stock has a market capitalization of $843.38 million, a price-to-earnings ratio of 29.83 and a beta of 1.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.59 and a quick ratio of 3.36. Eagle Pharmaceuticals has a 1 year low of $36.03 and a 1 year high of $63.45.
In other Eagle Pharmaceuticals news, Director Hudson Executive Capital Lp sold 1,112 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $60.06, for a total value of $66,786.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 31,693 shares of company stock worth $1,949,432 in the last 90 days. Company insiders own 31.70% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Marshall Wace North America L.P. lifted its holdings in shares of Eagle Pharmaceuticals by 57.8% in the 1st quarter. Marshall Wace North America L.P. now owns 5,956 shares of the specialty pharmaceutical company’s stock worth $301,000 after purchasing an additional 2,182 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $314,000. Scout Investments Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 79.7% in the 2nd quarter. Scout Investments Inc. now owns 98,810 shares of the specialty pharmaceutical company’s stock worth $5,502,000 after purchasing an additional 43,815 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $206,000. Finally, Foundry Partners LLC lifted its holdings in shares of Eagle Pharmaceuticals by 865.6% in the 2nd quarter. Foundry Partners LLC now owns 73,385 shares of the specialty pharmaceutical company’s stock worth $4,086,000 after purchasing an additional 65,785 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Further Reading: What is required to own or exchange cryptocurrency?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.